You are here: Industry Insights > PTCL

News List

Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat) prnasia
January 24, 2022
IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS.
Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma FirstWordPharma
December 14, 2021
Newswise — The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being..
BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma pharmatimes
August 06, 2021
Celgene (now a subsidiary of Bristol Myers Squibb) received accelerated FDA approval in 2011 for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who ...
Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL) pharmafocusasia
December 03, 2018
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer......
FDA approves treatment for peripheral T-cell lymphoma europeanpharmaceuticalreview
November 20, 2018
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program…